Madrigal Pharmaceuticals, Inc.
MDGL
$546.66
$12.502.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 364.25M | 311.34M | 321.08M | 287.27M | 212.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 364.25M | 311.34M | 321.08M | 287.27M | 212.80M |
| Cost of Revenue | 40.01M | 26.85M | 24.45M | 18.12M | 9.07M |
| Gross Profit | 324.25M | 284.49M | 296.64M | 269.15M | 203.74M |
| SG&A Expenses | 289.38M | 268.52M | 239.98M | 209.12M | 196.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 420.56M | 404.06M | 380.69M | 401.24M | 260.00M |
| Operating Income | -56.31M | -92.72M | -59.61M | -113.98M | -47.20M |
| Income Before Tax | -57.94M | -94.39M | -58.58M | -114.19M | -42.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.94M | -94.39M | -58.58M | -114.19M | -42.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.94M | -94.39M | -58.58M | -114.19M | -42.28M |
| EBIT | -56.31M | -92.72M | -59.61M | -113.98M | -47.20M |
| EBITDA | -55.93M | -92.34M | -59.22M | -113.62M | -46.83M |
| EPS Basic | -2.51 | -3.25 | -2.57 | -5.08 | -1.90 |
| Normalized Basic EPS | -1.57 | -2.03 | -1.60 | -3.10 | -1.19 |
| EPS Diluted | -2.51 | -3.25 | -2.57 | -5.08 | -1.90 |
| Normalized Diluted EPS | -1.57 | -2.03 | -1.60 | -3.10 | -1.19 |
| Average Basic Shares Outstanding | 23.07M | 29.03M | 22.83M | 22.48M | 22.21M |
| Average Diluted Shares Outstanding | 23.07M | 29.03M | 22.83M | 22.48M | 22.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |